Hechenberger, Stefanie http://orcid.org/0000-0002-2839-4000
Helmlinger, Birgit http://orcid.org/0000-0001-5022-2910
Tinauer, Christian http://orcid.org/0000-0003-4355-3898
Jauk, Emanuel http://orcid.org/0000-0003-3267-1688
Ropele, Stefan http://orcid.org/0000-0002-5559-768X
Heschl, Bettina
Wurth, Sebastian http://orcid.org/0000-0001-7122-0842
Damulina, Anna http://orcid.org/0000-0001-8241-2727
Eppinger, Sebastian
Demjaha, Rina http://orcid.org/0000-0001-9725-9809
Khalil, Michael http://orcid.org/0000-0002-5350-3328
Enzinger, Christian http://orcid.org/0000-0001-9764-7617
Pinter, Daniela http://orcid.org/0000-0003-3138-5225
Funding for this research was provided by:
Biogen (AT-MSG-11729)
Medical University of Graz
Article History
Received: 8 January 2024
Revised: 21 February 2024
Accepted: 23 February 2024
First Online: 5 March 2024
Declarations
:
: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. S.H. has received speaking honoraria from Roche and Bristol-Myers Squibb. B.H. has received funding for travel from Janssen and speaking honoraria from Roche and Bristol-Myers Squibb. C.T. has no relevant financial or non-financial interests to disclose. E.J. has no relevant financial or non-financial interests to disclose. S.R. has no relevant financial or non-financial interests to disclose. B.H. has received funding for travel or speaker honoraria from Bayer, Biogen, Bristol-Myers Squibb, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. S.W. has no relevant financial or non-financial interests to disclose. A.D. has received speaker honoraria from Sanofi-Aventis and travel funding from Novartis. S.E. has no relevant financial or non-financial interests to disclose. R.D. has no relevant financial or non-financial interests to disclose. M.K. has received funding for travel and speaker honoraria from Bayer Schering Pharma, Novartis Genzyme, Merck Serono, Biogen Idec and Teva Pharmaceutical Industries Ltd. and a research grant from Teva Pharmaceutical Industries Ltd. C.E. received funding for traveling and speaker honoraria from Biogen Idec, Bayer Schering Pharma, Merck Serono, Novartis, Genzyme and Teva Pharmaceutical Industries Ltd./sanofi-aventis, Shire; received research support from Merck Serono, Biogen Idec, and Teva Pharmaceutical Industries Ltd./sanofi-aventis; and serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Genzyme, Roche, and Teva Pharmaceutical Industries Ltd./sanofi- Aventis. D.P. has received funding for travel from Merck, Genzyme/Sanofi-Aventis and Biogen, as well as speaking honoraria from Biogen, Bristol-Myers Squibb, Novartis and Merck.
: The study was performed in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the ethics committee of the Medical University of Graz (permit number 31–432 ex 18/19 1264–2019).
: Informed consent was obtained from all individual participants included in the study.
: All data are anonymized.